One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Delayed diagnosis in axial spondyloarthritis—how can we do better?
Karl Gaffney, Dale Webb, Raj Sengupta
doi : 10.1093/rheumatology/keab496
Rheumatology, Volume 60, Issue 11, November 2021, Pages 4951–4952
Rheumatologists at a crossroads: blocking tumour necrosis factor or interleukin 6 in disease-modifying anti-rheumatic drug inadequate responder patients with rheumatoid arthritis
Luca Quartuccio, Ernest H Choy
doi : 10.1093/rheumatology/keab425
Rheumatology, Volume 60, Issue 11, November 2021, Pages 4953–4955
The scleromyositis phenotype. Lessons from a multicentre international cohort of anti-PM/Scl–positive patients
Albert Selva-O’Callaghan, Carmen Pilar Simeon-Aznar
doi : 10.1093/rheumatology/keab433
Rheumatology, Volume 60, Issue 11, November 2021, Pages 4956–4957
Diagnosing giant cell arteritis: a comprehensive practical guide for the practicing rheumatologist
Peter M Andel, Stavros Chrysidis, Julia Geiger, Anne C Bull Haaversen, Glenn Haugeberg, Geirmund Myklebust, Berit D Nielsen, Andreas P Diamantopoulos
doi : 10.1093/rheumatology/keab547
Rheumatology, Volume 60, Issue 11, November 2021, Pages 4958–4971
GCA is the most common large vessel vasculitis in the elderly population. In recent years, advanced imaging has changed the way GCA can be diagnosed in many locations. The GCA fast-track clinic approach combined with US examination allows prompt treatment and diagnosis with high certainty. Fast-track clinics have been shown to improve prognosis while being cost effective. However, all diagnostic modalities are highly operator dependent, and in many locations expertise in advanced imaging may not be available. In this paper, we review the current evidence on GCA diagnostics and propose a simple algorithm for diagnosing GCA for use by rheumatologists not working in specialist centres.
Targeted literature review of current treatments and unmet need in moderate rheumatoid arthritis in the United Kingdom
Peter C Taylor, Matthew Woods, Catherine Rycroft, Priya Patel, Sophee Blanthorn-Hazell, Toby Kent, Marwan Bukhari
doi : 10.1093/rheumatology/keab464
Rheumatology, Volume 60, Issue 11, November 2021, Pages 4972–4981
The burden and treatment landscape of RA is poorly understood. This research aimed to identify evidence on quality of life, caregiver burden, economic burden, treatment patterns and clinical outcomes for patients with moderate RA in the United Kingdom.
A systematic review and meta-analysis of the incidence rate of Takayasu arteritis
Megan Rutter, Jonathan Bowley, Peter C Lanyon, Matthew J Grainge, Fiona A Pearce
doi : 10.1093/rheumatology/keab406
Rheumatology, Volume 60, Issue 11, November 2021, Pages 4982–4990
Takayasu arteritis (TAK) is a rare autoimmune rheumatic disease causing large-vessel vasculitis. Onset is typically between the ages of 20 and 30 years. It is associated with substantial morbidity and mortality, notably due to its effects on the cardiovascular system. It has a poorly understood global epidemiology. Our objective was to systematically review the available evidence in order to calculate the incidence rate of TAK.
Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors
Roy Fleischmann, Mark C Genovese, Karina Maslova, Henry Leher, Amy Praestgaard, Gerd R Burmester
doi : 10.1093/rheumatology/keab355
Rheumatology, Volume 60, Issue 11, November 2021, Pages 4991–5001
The objective of this study was to evaluate the long-term safety and efficacy of sarilumab over 5?years in patients with RA refractory to TNF inhibitors (TNFis).
Intensive and app-delivered occupational therapy to improve upper extremity function in early diffuse cutaneous systemic sclerosis: a pilot two-arm trial
Susan L Murphy, Mary Barber, Suiyuan Huang, Maya Sabbagh, Gary Cutter, Dinesh Khanna
doi : 10.1093/rheumatology/keab339
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5002–5011
SSc reduces upper extremity function and performance of everyday activities; however, there are few evidence-based rehabilitation interventions. This study examined short and longer-term effects of two occupational therapy interventions on hand disability.
Characteristics associated between the incidence of hip osteoarthritis and early hip complaints (CHECK study) within 10 years
Annemaria C van Berkel, Dieuwke Schiphof, Jan H Waarsing, Jos Runhaar, John M van Ochten, Patrick J E Bindels, Sita M A Bierma-Zeinstra
doi : 10.1093/rheumatology/keab137
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5012–5019
To determine which baseline characteristics, especially clinically variables like pain, stiffness, physical functioning and disease variables, are associated with incident hip OA within 10 years in first presenters with hip complaints.
Effects of fenofibrate therapy on renal function in primary gout patients
Xinde Li, Wenyan Sun, Jie Lu, Yuwei He, Ying Chen, Wei Ren, Lingling Cui, Zhen Liu, Can Wang, Xuefeng Wang, Lidan Ma, Xiaoyu Cheng, Lin Han, Hailong Li, Hui Zhang, Xuan Yuan, Xiaopeng Ji, Aichang Ji, Tony R Merriman, Changgui Li
doi : 10.1093/rheumatology/keab231
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5020–5027
To investigate the incidence and potential risk factors for development of fenofibrate-associated nephrotoxicity in gout patients.
The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort
Maria-Grazia Lazzaroni, Emiliano Marasco, Corrado Campochiaro, Jeska DeVries-Bouwstra, Montserrat-Ixchel Gonzalez-Perez, Jorge Rojas-Serrano, Eric Hachulla, Elisabetta Zanatta, Simone Barsotti, Federica Furini, Konstantinos Triantafyllias, Giuseppina Abignano, Marie-Elise Truchetet, Giacomo De Luca, Ellen De Langhe, Roger Hesselstrand, Francesca Ingegnoli, Eugenia Bertoldo, Vanessa Smith, Silvia Bellando-Randone, Hadi Poormoghim, Enrico Colombo, Angela Ceribelli, Alessio Furloni, Stefania Zingarelli, Ilaria Cavazzana, Franco Franceschini, Francesco Del Galdo, Christopher P Denton, Lorenzo Cavagna, Oliver Distler, Yannick Allanore, Paolo Airò, for the EUSTAR co-authors
doi : 10.1093/rheumatology/keab152
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5028–5041
To evaluate clinical associations of anti-PM/Scl antibodies in patients with SSc in a multicentre international cohort, with particular focus on unresolved issues, including scleroderma renal crisis (RC), malignancies, and functional outcome of interstitial lung disease (ILD).
Use of disease-modifying antirheumatic drugs and the subsequent risk of herpes zoster in older adults
Jiahui Qian, Marissa Nichole Lassere, Anita Elizabeth Heywood, Bette Liu
doi : 10.1093/rheumatology/keab538
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5042–5051
To examine the association between DMARD use and subsequent risk of herpes zoster in a large, heterogeneous and prospective population-based cohort.
Quantitative ultrasound to monitor the vascular response to tocilizumab in giant cell arteritis
Luca Seitz, Lisa Christ, Fabian Lötscher, Godehard Scholz, Adela-Cristina Sarbu, Lukas Bütikofer, Florian Kollert, Wolfgang A Schmidt, Stephan Reichenbach, Peter M Villiger
doi : 10.1093/rheumatology/keab484
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5052–5059
To characterize the effect of ultra-short glucocorticoids followed by Tocilizumab monotherapy on the intima-media thickness (IMT) in GCA.
Sexual function in patients with idiopathic inflammatory myopathies: a cross-sectional study
Barbora He?mánková, Maja Špiritovi?, Sabína Oreská, Hana Štorkánová, Martin Komarc, Martin Klein, He?man Mann, Karel Pavelka, Ladislav Šenolt, Ji?í Vencovský, Michal Tom?ík
doi : 10.1093/rheumatology/keab397
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5060–5072
To date, there is almost no information concerning the sexual health of patients with idiopathic inflammatory myopathies (IIM). This cross-sectional study aimed to compare sexual function in patients with IIM to age-/sex-matched healthy controls (HC) and determine the potential impact of clinical features on sexual function.
Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort
Bernard Combe, Nathalie Rincheval, Francis Berenbaum, Patrick Boumier, Alain Cantagrel, Philippe Dieude, Maxime Dougados, Bruno Fautrel, René-Marc Flipo, Philippe Goupille, Xavier Mariette, Alain Saraux, Thierry Schaeverbeke, Jean Sibilia, Olivier Vittecoq, Jean-Pierre Daurès
doi : 10.1093/rheumatology/keab398
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5073–5079
To report the 10-year outcome of an inception cohort of patients with early rheumatoid arthritis (RA), the ESPOIR cohort, and predictors of outcome.
Real-life analysis of the causes of death in patients consecutively followed for giant cell arteritis in a French centre of expertise
Luca Antonini, Anael Dumont, Amandine Lavergne, Paul Castan, Clivia Barakat, Sophie Gallou, Audrey Sultan, Samuel Deshayes, Achille Aouba, Hubert de Boysson
doi : 10.1093/rheumatology/keab222
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5080–5088
To describe, in a real-life setting, the direct causes of death in a cohort of consecutive patients with GCA.
Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study
Yanwei Lin, Xiaoxiang Chen, Huihua Ding, Ping Ye, Jieruo Gu, Xiaoxia Wang, Zhenyu Jiang, Detian Li, Zhongming Wang, Wubin Long, Zhijun Li, Gengru Jiang, Xiaomei Li, Liqi Bi, Lindi Jiang, Jian Wu, Lian Guo, Xiaoyan Cai, Xin Lu, Qinkai Chen, Hong Chen, Ai Peng, Xiaoxia Zuo, Rui Ning, Zhe Zhang, Yanfei Tai, Tao Zhang, Chunde Bao
doi : 10.1093/rheumatology/keab198
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5089–5097
To evaluate the efficacy and safety of SHR4640, a highly selective urate transporter 1 inhibitor, in Chinese subjects with hyperuricaemia.
Diagnosing axial spondyloarthritis: estimation of the disease probability in patients with a priori different likelihoods of the diagnosis
Denis Poddubnyy, Fabian Proft, Laura Spiller, Mikhail Protopopov, Valeria Rios Rodriguez, Burkhard Muche, Judith Rademacher, Murat Torgutalp, Janis Lucas Vahldiek, Joachim Sieper, Imke Redeker
doi : 10.1093/rheumatology/keab227
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5098–5104
To evaluate the diagnostic value of SpA parameters and their combination for the diagnosis of axial SpA in patients with an a priori different probability of the diagnosis.
Non-adherence in difficult-to-treat rheumatoid arthritis from the perspectives of patients and rheumatologists: a concept mapping study
Nadia M T Roodenrijs, Marlies C van der Goes, Paco M J Welsing, Eline P C van Oorschot, Elena Nikiphorou, Nienke C Nijhof, Janneke Tekstra, Floris P J G Lafeber, Johannes W G Jacobs, Jacob M van Laar, Rinie Geenen
doi : 10.1093/rheumatology/keab130
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5105–5116
Treatment non-adherence is more frequent among difficult-to-treat (D2T) than among non-D2T RA patients. Perceptions of non-adherence may differ. We aimed to thematically structure and prioritize barriers to (i.e. causes and reasons for non-adherence) and facilitators of optimal adherence from the patients’ and rheumatologists’ perspectives.
Association of particulate matter with autoimmune rheumatic diseases among adults in South Korea
Jun Seok Park, Seulggie Choi, Kyuwoong Kim, Jooyoung Chang, Sung Min Kim, Seong Rae Kim, Gyeongsil Lee, Joung Sik Son, Kyae Hyung Kim, Eun Young Lee, Sang Min Park
doi : 10.1093/rheumatology/keab127
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5117–5126
The primary objective of this study was to investigate adverse effects of ambient particulate matter of various sizes on the incidence of the prevalent autoimmune rheumatic diseases (AIRDs): RA, AS and SLE.
Trend in women representation among authors of high rank rheumatology journals articles, 2002–2019
Yoel Levinsky, Yoav Vardi, Michal Gafner, Neta Cohen, Michael Mimouni, Oded Scheuerman, Daniel E Furst, Gil Amarilyo
doi : 10.1093/rheumatology/keab134
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5127–5133
The representation of women among authors of peer reviewed scientific papers is gradually increasing. The aims of this study were to examine the trend of the proportion of women among authors in the field of rheumatology during the last two decades.
Early predictors of renal outcome in patients with proliferative lupus nephritis: a 36-month cohort study
Mariana S F Luís, Irene E M Bultink, José A P da Silva, Alexandre E Voskuyl, Luís S Inês
doi : 10.1093/rheumatology/keab126
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5134–5141
To identify predictors of complete renal response (CRR) and renal flares in SLE patients with active proliferative LN.
Performance of 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in a paediatric population—a multicentre study
Yoel Levinsky, Mor Broide, Shelly Kagan, Ori Goldberg, Oded Scheuerman, Rotem Tal, Irit Tirosh, Yoni Butbul, Daniel E Furst, Liora Harel, Gil Amarilyo
doi : 10.1093/rheumatology/keab140
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5142–5148
The European League Against Rheumatism and American College of Rheumatology 2019 (EULAR/ACR-19) criteria for the diagnosis of SLE were recently published, with the stated goal of maintaining the level of sensitivity and raising the level of specificity for classification of SLE in adults. The aim of this study is to examine their application to juvenile SLE (jSLE) patients.
Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients
Tiphaine Lenfant, Yuxuan Jin, Elizabeth Kirchner, Rula A Hajj-Ali, Leonard H Calabrese, Cassandra Calabrese
doi : 10.1093/rheumatology/keab139
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5149–5157
To provide insight into the safety of recombinant zoster vaccine (RZV) in patients with immune-mediated inflammatory diseases (IMID).
Diagnostic criteria for early hip osteoarthritis: first steps, based on the CHECK study
Jos Runhaar, Ömer Özbulut, Margreet Kloppenburg, Maarten Boers, Johannes W J Bijlsma, Sita M A Bierma-Zeinstra, the CREDO expert group
doi : 10.1093/rheumatology/keab111
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5158–5164
Although there is a general focus on early diagnosis and treatment of hip OA, there are no validated diagnostic criteria for early-stage hip OA. The current study aimed to take the first steps in developing diagnostic criteria for early-stage hip OA, using factors obtained through history taking, physical examination, radiography and blood testing at the first consultation in individuals presenting with hip pain, suspicious for hip OA, in primary care.
A dysregulated interleukin-18–interferon-?–CXCL9 axis impacts treatment response to canakinumab in systemic juvenile idiopathic arthritis
Tanja Hinze, Christoph Kessel, Claas H Hinze, Julia Seibert, Hermann Gram, Dirk Foell
doi : 10.1093/rheumatology/keab113
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5165–5174
The monoclonal IL-1? antibody canakinumab is approved for the treatment of systemic juvenile idiopathic arthritis (SJIA). Its efficacy has been proven in several trials, but not all patients show a complete and sustained response to therapy. We aimed to analyse the association of baseline serum biomarkers with treatment outcome in patients with SJIA treated with canakinumab.
Factors associated with longitudinal change of meniscal extrusion in overweight women without clinical signs of osteoarthritis
Jan A van der Voet, Daan Wesselius, Fan Zhang, Dammis Vroegindeweij, Edwin H Oei, Sita M A Bierma-Zeinstra, Martin Englund, Jos Runhaar
doi : 10.1093/rheumatology/keab228
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5175–5184
To identify variables associated with longitudinal change in meniscal extrusion, which might be used as possible targets for knee osteoarthritis (KOA) prevention.
Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational study
Rangi Kandane-Rathnayake, Worawit Louthrenoo, Vera Golder, Shue-Fen Luo, Yeong-Jian J Wu, Aisha Lateef, Jiacai Cho, Zhanguo Li, Yuan An, Laniyati Hamijoyo, Sandra Navarra, Leonid Zamora, Yasuhiro Katsumata, Masayoshi Harigai, Sargunan Sockalingam, Madelynn Chan, Yi-Hsing Chen, Sean O'Neill, Fiona Goldblatt, Yanjie Hao, Zhuoli Zhang, Jun Kikuchi, Tsutomu Takeuchi, Chak Sing Lau, Mandana Nikpour, Eric Morand, Alberta Hoi, for the Asia Pacific Lupus Collaboration
doi : 10.1093/rheumatology/keab217
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5185–5193
The prevalence and associations of leucopenia in SLE remain incompletely understood. We evaluated associations of disease activity and medication use with leucopenia (lymphopenia and neutropenia) in a multinational, prospectively followed SLE cohort.
Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study
Khaled Mahmoud, Ahmed S Zayat, Md Yuzaiful Md Yusof, Katherine Dutton, Lee Suan Teh, Chee-Seng Yee, David D’Cruz, Nora Ng, David Isenberg, Coziana Ciurtin, Philip G Conaghan, Paul Emery, Christopher J Edwards, Elizabeth M A Hensor, Edward M Vital
doi : 10.1093/rheumatology/keab288
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5194–5204
To determine whether SLE patients with inflammatory joint symptoms and US synovitis/tenosyovitis achieve better clinical responses to glucocorticoids compared with patients with normal scans. Secondary objectives included identification of clinical features predicting US synovitis/tenosynovitis.
Patients with rheumatoid arthritis have impaired long-term outcomes after myocardial infarction: a nationwide case-control registry study
Antti Palomäki, Anne M Kerola, Markus Malmberg, Päivi Rautava, Ville Kytö
doi : 10.1093/rheumatology/keab204
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5205–5215
To investigate the long-term outcomes of patients with RA after myocardial infarction (MI).
Is pain associated with premature mortality in patients with psoriatic arthritis? A nested case–control study using the DANBIO Register
Jonathan Vela, Rene Lindholm Cordtz, Salome Kristensen, Christian Torp-Pedersen, Kristian Kjær Petersen, Lars Arendt-Nielsen, Lene Dreyer
doi : 10.1093/rheumatology/keab192
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5216–5223
It has been hypothesized that the presence of chronic pain causes excess mortality. Since chronic pain is prevalent among patients with PsA this potential association should be explored. We aimed to investigate whether higher cumulative pain intensity is associated with an excess mortality risk in patients with PsA.
Substantial anti-gout effect conferred by common and rare dysfunctional variants of URAT1/SLC22A12
Yu Toyoda, Yusuke Kawamura, Akiyoshi Nakayama, Hirofumi Nakaoka, Toshihide Higashino, Seiko Shimizu, Hiroshi Ooyama, Keito Morimoto, Naohiro Uchida, Ryuichiro Shigesawa, Kenji Takeuchi, Ituro Inoue, Kimiyoshi Ichida, Hiroshi Suzuki, Nariyoshi Shinomiya, Tappei Takada, Hirotaka Matsuo
doi : 10.1093/rheumatology/keab327
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5224–5232
Gout, caused by chronic elevation of serum uric acid levels, is the commonest form of inflammatory arthritis. The causative effect of common and rare variants of ATP-binding cassette transporter G2 (ABCG2/BCRP) on gout risk has been studied, but little attention has been paid to the effect of common (rs121907892, p.W258X) and rare variants of urate transporter 1 (URAT1/SLC22A12) on gout, despite dysfunctional variants of URAT1 having been identified as pathophysiological causes of renal hypouricaemia.
Secukinumab as a potential trigger of inflammatory bowel disease in ankylosing spondylitis or psoriatic arthritis patients
Ioana A Onac, Benjamin D Clarke, Cristina Tacu, Mark Lloyd, Vijay Hajela, Thomas Batty, Jamie Thoroughgood, Sandra Smith, Hannah Irvine, Diane Hill, Grace Baxter, Natalie Horwood, Suma Mahendrakar, Rizwan Rajak, Sian Griffith, Patrick D W Kiely, James Galloway
doi : 10.1093/rheumatology/keab193
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5233–5238
Real-world secukinumab gastrointestinal-related adverse events (GIRAE) data during treatment for AS and PsA are lacking. We aimed to obtain this through baseline evaluation of pre-existing IBD rates and predictors of GIRAE.
Medication adherence in older people with rheumatoid arthritis is lower according to electronic monitoring than according to pill count
Linda Hartman, Maurizio Cutolo, Reinhard Bos, Daniela Opris-Belinski, Marc R Kok, Hanneke (J) R M Griep-Wentink, Ruth Klaasen, Cornelia F Allaart, George A W Bruyn, Hennie G Raterman, Marieke J H Voshaar, Nuno Gomes, Rui M A Pinto, L Thomas Klausch, Willem F Lems, M Boers
doi : 10.1093/rheumatology/keab207
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5239–5246
Suboptimal medication adherence is a serious problem in the treatment of chronic inflammatory diseases. To measure medication adherence, electronic monitoring is regarded as superior to pill count. GLORIA is an ongoing two-year trial on the addition of low-dose (5?mg/d) prednisolone or placebo to standard care in older people (65+ years) with RA. During the entire trial, adherence is measured with electronic caps, and with pill counts. The objective is to describe medication adherence patterns, and to compare the adherence results of the two methods.
Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice
Satoshi Takanashi, Yuko Kaneko, Tsutomu Takeuchi
doi : 10.1093/rheumatology/keab209
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5247–5256
The aim of this study was to investigate the clinical characteristics of patients with difficult-to-treat RA (D2T RA) and the usefulness of switching to drugs with different modes of action in real-world.
Barriers and facilitators to influenza and pneumococcal vaccine hesitancy in rheumatoid arthritis: a qualitative study
Inés Colmegna, Valeria Valerio, Vincent Gosselin-Boucher, Guillaume Lacoste, Sara Labbe, Kim L Lavoie, Elizabeth Hazel, Brian Ward, Marie Hudson, Sandra Peláez
doi : 10.1093/rheumatology/keab471
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5257–5270
Immunization is an essential component of RA care. Nevertheless, vaccine coverage in RA is suboptimal. Contextual, individual and vaccine-related factors influence vaccine acceptance. However, barriers and facilitators of vaccination in RA are not well defined. The aim of this study was to assess perspectives of RA patients and healthcare professionals (HCPs) involved in RA care of barriers and facilitators regarding influenza and pneumococcal vaccines.
Limited sensitivity and specificity of the ACR/EULAR-2019 classification criteria for SLE in JSLE?—observations from the UK JSLE Cohort Study
Eve M D Smith, Sajida Rasul, Coziana Ciurtin, Eslam Al-Abadi, Kate Armon, Kathryn Bailey, Mary Brennan, Janet Gardner-Medwin, Kirsty Haslam, Daniel P Hawley, Steven Lane, Alice Leahy, Valentina Leone, Gulshan Malik, Devesh Mewar, Robert Moots, Clarissa Pilkington, Athimalaipet V Ramanan, Satyapal Rangaraj, Annie Ratcliffe, Phil Riley, Ethan Sen, Arani Sridhar, Nick Wilkinson, Michael W Beresford, Liza J McCann, Christian M Hedrich
doi : 10.1093/rheumatology/keab210
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5271–5281
This study aimed to test the performance of the new ACR and EULAR criteria, that include ANA positivity as entry criterion, in JSLE.
Quantification of morning stiffness to assess disease activity and treatment effects in rheumatoid arthritis
Heide Boeth, Robert Biesen, Jeremias Hollnagel, Sandra Herrmann, Rainald M Ehrig, Lorenzo Pelli, William R Taylor, Georg N Duda, Frank Buttgereit
doi : 10.1093/rheumatology/keab323
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5282–5291
The clinical parameter of morning stiffness is widely used to assess the status of RA, but its accurate quantitative assessment in a clinical setting has not yet been successful. This lack of individual quantification limits both personalized medication and efficacy evaluation in the treatment of RA.
What?influences patients’ opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study
Laura C Coates, Danielle E Robinson, Ana-Maria Orbai, Uta Kiltz, Ying-Ying Leung, Penelope Palominos, Juan D Cañete, Rossana Scrivo, Andra Balanescu, Emmanuelle Dernis, Sandra Meisalu, Adeline Ruyssen-Witrand, Lihi Eder, Maarten de Wit, Josef S Smolen, Ennio Lubrano, Laure Gossec
doi : 10.1093/rheumatology/keab220
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5292–5299
In PsA, the treatment objective is remission or low disease activity (LDA), but patients’ perception of remission is poorly studied. This analysis aimed to identify factors associated with patient-defined remission.
Increased risk of severe infections and mortality in patients with newly diagnosed systemic lupus erythematosus: a population-based study
Kai Zhao, Hui Xie, Lingyi Li, John M Esdaile, J Antonio Aviña-Zubieta
doi : 10.1093/rheumatology/keab219
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5300–5309
To evaluate the risk of severe infection and infection-related mortality among patients with newly diagnosed SLE.
The association of smoking with immunoglobulin G4–related disease: a case–control study
Rachel Wallwork, Cory A Perugino, Xiaoqing Fu, Tyler Harkness, Yuqing Zhang, Hyon K Choi, John H Stone, Zachary S Wallace
doi : 10.1093/rheumatology/keab172
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5310–5317
To evaluate the association between cigarette smoking and the odds of IgG4-related disease (IgG4-RD).
Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)
Frank Behrens, Michaela Koehm, Tanja Rossmanith, Rieke Alten, Martin Aringer, Marina Backhaus, Gerd R Burmester, Eugen Feist, Eva Herrmann, Herbert Kellner, Klaus Krueger, Annette Lehn, Ulf Müller-Ladner, Andrea Rubbert-Roth, Hans-Peter Tony, Siegfried Wassenberg, Harald Burkhardt
doi : 10.1093/rheumatology/keab153
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5318–5328
To investigate the efficacy and safety of rituximab + LEF in patients with RA.
Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?
Beatriz Tejera Segura, Irene Altabás González, Iñigo Rúa-Figueroa, Natalia Pérez Veiga, Victor Del Campo Pérez, Alejandro Olivé-Marqués, María Galindo, Jaime Calvo, Juan Gabriel Ovalles-Bonilla, Antonio Fernández-Nebro, Raúl Menor-Almagro, Eva Tomero, Natividad del Val del Amo, Esther Uriarte Isacelaya, Víctor Manuel Martínez-Taboada, Jose L Andreu, Alina Boteanu, Javier Narváez, Atusa Movasat, Carlos Montilla, Jose Miguel Senabre Gallego, Blanca Hernández-Cruz, Mariano Andrés, Eva Salgado, Mercedes Freire, Sergio Machín García, Clara Moriano, Lorena Expósito, Clara Pérez Velásquez, M L Velloso-Feijoo, Ana Paula Cacheda, Nuria Lozano-Rivas, Gema Bonilla, Marta Arévalo, Inmaculada Jiménez, Víctor Quevedo-Vila, Francisco J Manero-Ruiz, Paloma García de la Peña Lefebvre, Tomás Ramón Vázquez-Rodríguez, Jesús Ibañez-Rua, Tatiana Cobo-Ibañez, Jose María Pego-Reigosa
doi : 10.1093/rheumatology/keab401
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5329–5336
SLE can affect any part of the gastrointestinal (GI) tract. GI symptoms are reported to occur in >50% of SLE patients. To describe the GI manifestations of SLE in the RELESSER (Registry of SLE Patients of the Spanish Society of Rheumatology) cohort and to determine whether these are associated with a more severe disease, damage accrual and a worse prognosis.
Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies
Dennis McGonagle, Iain B McInnes, Atul Deodhar, Georg Schett, May Shawi, Shelly Kafka, Chetan S Karyekar, Alexa P Kollmeier, Elizabeth C Hsia, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Christopher T Ritchlin, Proton Rahman, Philip J Mease
doi : 10.1093/rheumatology/keab285
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5337–5350
To further characterize the effect of guselkumab, a selective IL-23p19-subunit inhibitor approved for PsA, on enthesitis and assess relationships between enthesitis resolution and patient status/outcomes.
Factors associated with incident severe pulmonary arterial hypertension in systemic autoimmune rheumatic diseases: a nationwide study
Hsin-Hua Chen, Ching-Heng Lin, Tsu-Yi Hsieh, Der-Yuan Chen, Jia-Ching Ying, Wen-Cheng Chao
doi : 10.1093/rheumatology/keab118
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5351–5361
To assess the association of severe pulmonary arterial hypertension (PAH) with particulate matter <2.5??m (p.m.2.5) and clinical data in patients with systemic autoimmune rheumatic diseases (SARDs).
Is the intima-media thickness of temporal and axillary arteries influenced by cardiovascular risk?
María Victoria Martire, Edoardo Cipolletta, Andrea Di Matteo, Marco Di Carlo, Diogo Jesus, Walter Grassi, Emilio Filippucci
doi : 10.1093/rheumatology/keab117
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5362–5368
To measure with US the intima-media thickness (IMT) of temporal (superficial, parietal and frontal branches) and axillary arteries in subjects without a diagnosis of GCA and/or PMR with different cardiovascular (CV) risk; and to assess the performance of previously proposed cut-off values for normal IMT.
Association of clinical characteristics, disease activity and health-related quality of life in SLE patients with major depressive disorder
Konstantinos Parperis, Savvas Psarelis, Andreas Chatzittofis, Michalis Michaelides, Dimitra Nikiforou, Elpida Antoniade, Bikash Bhattarai
doi : 10.1093/rheumatology/keab123
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5369–5378
To determine the contributing factors associated with major depressive disorder (MDD) in SLE patients and examine the association between disease-specific health-related quality of life [lupus quality of life (LupusQoL)] domains and MDD.
Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus
Daniel J Wallace, David A Isenberg, Eric F Morand, Cristina Vazquez–Mateo, Amy H Kao, Aida Aydemir, Kishore Pudota, Victor Ona, Cynthia Aranow, Joan T Merrill
doi : 10.1093/rheumatology/keab115
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5379–5389
Atacicept reduced SLE disease activity in the phase 2b ADDRESS II study, particularly in patients with high disease activity (HDA; SLEDAI-2K ?10) at screening. We assessed long-term safety and efficacy of atacicept in the long-term extension (LTE) of ADDRESS II.
Sub-setting systemic lupus erythematosus by combined molecular phenotypes defines divergent populations in two phase III randomized trials
Michelle Petri, Steven D Watts, Richard E Higgs, Matthew D Linnik
doi : 10.1093/rheumatology/keab144
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5390–5396
Heterogeneity of SLE patients in clinical trials remains a challenge for developing new therapies. This study used a combinatorial analysis of four molecular biomarkers to define key sources of heterogeneity.
Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus
Richard A Furie, Ian N Bruce, Thomas Dörner, Manuel Gustavo Leon, Piotr Leszczy?ski, Murray Urowitz, Birgit Haier, Teri Jimenez, Claire Brittain, Jiajun Liu, Catherine Barbey, Christian Stach
doi : 10.1093/rheumatology/keab381
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5397–5407
To evaluate the dose–response, efficacy and safety of dapirolizumab pegol (DZP) in patients with SLE.
Heamatological malignancies in giant cell arteritis: a French population-based study
Hélène Greigert, Morgane Mounier, Louis Arnould, Catherine Creuzot-Garcher, André Ramon, Laurent Martin, Georges Tarris, Tibor Ponnelle, Sylvain Audia, Bernard Bonnotte, Marc Maynadie, Maxime Samson
doi : 10.1093/rheumatology/keab328
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5408–5412
An increased risk of haematological malignancies (HM) has been reported in GCA patients. Our study aimed to investigate the incidence and the type of HM occurring in GCA.
Peripheral ulcerative keratitis in rheumatoid arthritis patients taking tocilizumab: paradoxical manifestation or insufficient efficacy?
Florian Cohen, Eric Ernest Gabison, Sophie Stéphan, Rakiba Belkhir, Gaetane Nocturne, Anne-Laurence Best, Oscar Haigh, Emmanuel Barreau, Marc Labetoulle, Raphaele Seror, Antoine Rousseau
doi : 10.1093/rheumatology/keab093
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5413–5418
Peripheral ulcerative keratitis (PUK) is a severe corneal condition associated with uncontrolled RA. Tocilizumab (TCZ) is used to control RA, however, episodes of paradoxical ocular inflammation have been reported in TCZ-treated patients. We report a case series of PUK in TCZ-treated RA patients with ophthalmological and systemic findings and discuss the potential underlying mechanisms.
Comparison of treatments and outcomes of children with juvenile dermatomyositis followed at two European tertiary care referral centers
Giulia Camilla Varnier, Alessandro Consolaro, Susan Maillard, Clarissa Pilkington, Angelo Ravelli
doi : 10.1093/rheumatology/keab089
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5419–5423
To compare the treatment approaches and disease outcomes of children with JDM followed in two European tertiary care peadiatric rheumatology centres.
Comprehensive microRNA and transcriptomic profiling of rheumatoid arthritis monocytes: role of microRNA-146b in pro-inflammatory progression
Marzena Ciechomska, Bartosz Wojtas, Krzysztof Bonek, Leszek Roszkowski, Piotr Gluszko, Vladimir Benes, Wlodzimierz Maslinski
doi : 10.1093/rheumatology/keab407
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5424–5435
To explore global miRNA and transcriptomic profiling of monocytes from RA patients compared with healthy controls in order to predict which aberrantly expressed miRNA can negatively modulate inflammatory molecules.
Phenotypic analysis of pyrin-associated autoinflammation with neutrophilic dermatosis patients during treatment
Erika Van Nieuwenhove, Ellen De Langhe, James Dooley, Joost Van Den Oord, Mohammad Shahrooei, Nima Parvaneh, Vahid Ziaee, Sinisa Savic, Mark Kacar, Xavier Bossuyt, Stephanie Humblet-Baron, Adrian Liston, Carine Wouters
doi : 10.1093/rheumatology/keab221
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5436–5446
In 2016 specific heterozygous gain-of-function mutations in the Mediterranean fever gene MEFV were reported as causal for a distinct autoinflammatory disease coined pyrin-associated autoinflammation with neutrophilic dermatosis (PAAND). We sought to provide an extended report on clinical manifestations in PAAND patients to date and evaluate the efficacy and safety of treatment with the IL-1-blocking agent anakinra.
Clinical significance of E148Q heterozygous variant in paediatric familial Mediterranean fever
Irit Tirosh, Yonatan Yacobi, Asaf Vivante, Ortal Barel, Yishay Ben-Moshe, Ortal Erez Granat, Shiri Spielman, Rotem Semo Oz, Yael Shinar, Maya Gerstein
doi : 10.1093/rheumatology/keab128
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5447–5451
FMF results from mutations in the Mediterranean fever (MEFV) gene. The p. E148Q protein alternation is one of the most frequent in the MEFV gene, yet the exact E148Q genotype–phenotype correlation remains unclear. The aim of this study was to examine clinical significance of heterozygous E148Q variant in a paediatric FMF cohort.
Pathological role of activated mTOR in CXCR3+ memory B cells of rheumatoid arthritis
Shigeru Iwata, Mingzeng Zhang, Maiko Hajime, Naoaki Ohkubo, Koshiro Sonomoto, Keiichi Torimoto, Yukihiro Kitanaga, Gulzhan Trimova, Yasuyuki Todoroki, Hiroko Miyata, Masanobu Ueno, Atsushi Nagayasu, Ryuichiro Kanda, Kazuhisa Nakano, Shingo Nakayamada, Kei Sakata, Yoshiya Tanaka
doi : 10.1093/rheumatology/keab229
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5452–5462
B cells play an important pathological role in RA. In this study, we investigated the role of metabolic regulator mTOR in B cells and its relevance to the pathology of RA.
The inflammatory role of silent urate crystal deposition in intercritical gout
Cesar Diaz-Torne, M Angels Ortiz, Andrea Garcia-Guillen, Sicylle Jeria-Navarro, Lluís Sainz, Susana Fernandez-Sanchez, Hector Corominas, Silvia Vidal
doi : 10.1093/rheumatology/keab335
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5463–5472
To study subclinical inflammation in intercritical gout patients and its relation to the estimated size of monosodium urate crystal deposition and cardiovascular risk factors.
Ticagrelor added to methotrexate improves rheumatoid arthritis disease severity
Michael S Garshick, Pamela B Rosenthal, Elliot Luttrell-Williams, Bruce N Cronstein, Jeffrey S Berger
doi : 10.1093/rheumatology/keab481
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5473–5475
A patient with acute-onset hemorrhagic necroses and bullae of the legs
Hanna Graßhoff, Verena-Wilbeth Sailer, Jens Humrich, Gabriela Riemekasten, Peter Lamprecht
doi : 10.1093/rheumatology/keab399
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5476–5477
Mechanical thumb pain in a systemic sclerosis patient: simple first carpometacarpal osteoarthritis?
Guillaume Larid, Pier-Olivier Duboe, Jean-Denis Laredo, Elisabeth Gervais
doi : 10.1093/rheumatology/keab120
Rheumatology, Volume 60, Issue 11, November 2021, Page 5478
Disseminated tophaceous gout without renal impairment
Qiang Xu, Chang-Song Lin, Cong-Qiu Chu
doi : 10.1093/rheumatology/keab412
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5479–5480
Rare gastric manifestations in primary pachydermoperiostosis
Xia Chen, Chengde Yang, Ling Zhang, Qiongyi Hu
doi : 10.1093/rheumatology/keab100
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5481–5482
Corrigendum to: A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies
Alexander G S Oldroyd, Andrew B Allard, Jeffrey P Callen, Hector Chinoy, Lorinda Chung, David Fiorentino, Michael D George, Patrick Gordon, Kate Kolstad, Drew J B Kurtzman, Pedro M Machado, Neil J McHugh, Anna Postolova, Albert Selva-O’Callaghan, Jens Schmidt, Sarah Tansley, Ruth Ann Vleugels, Victoria P Werth, Rohit Aggarwal
doi : 10.1093/rheumatology/keab616
Rheumatology, Volume 60, Issue 11, November 2021, Page 5483
Corrigendum to: Patient and Rheumatologist Perspectives on Tapering DMARDs in Rheumatoid Arthritis: A Qualitative Study
Glen S Hazlewood, Adalberto Loyola-Sanchez, Vivian Bykerk, Pauline M Hull, Deborah Marshall, Tram Pham, Claire E H Barber, Cheryl Barnabe, Alexandra Sirois, Janet Pope, Orit Schieir, Dawn Richards, Laurie Proulx, Susan J Bartlett
doi : 10.1093/rheumatology/keab482
Rheumatology, Volume 60, Issue 11, November 2021, Page 5484
Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials
Mark C Genovese, Eduardo Mysler, Tetsuya Tomita, Kim A Papp, Carlo Salvarani, Sergio Schwartzman, Gaia Gallo, Himanshu Patel, Jeffrey R Lisse, Andris Kronbergs, Soyi Liu Leage, David H Adams, Wen Xu, Helena Marzo-Ortega, Mark G Lebwohl
doi : 10.1093/rheumatology/keab566
Rheumatology, Volume 60, Issue 11, November 2021, Page 5485
The role of IL-23 in joint disease
Georg Schett
doi : 10.1093/rheumatology/keab073
Rheumatology, Volume 60, Issue 11, November 2021, Pages 5486–5487
The myeloid cell-derived cytokine interleukin (IL-23) has been identified as an orchestrator of chronic inflammatory disease. IL-23 is instrumental in the activation of effector T cells and innate lymphoid cells, which in turn allow the mobilization of pro-inflammatory macrophages and neutrophils from the bone marrow and the initiation of inflammation in the joints, the gut and the skin. While the role of IL-23 in mounting chronic skin inflammation in the context of psoriasis is well established, increasing evidence suggests that also colitis and psoriatic arthritis are controlled by IL-23. Psoriasis, Crohn’s disease and psoriatic arthritis share a common genetic link to IL-23 receptor haplotypes and a therapeutic response to neutralization of IL-23. By controlling the expression of downstream effector cytokines IL-17A and TNFa, IL-23 triggers entheseal and synovial inflammation in patients with psoriatic arthritis by activating T cells and permitting the influx of macrophages and neutrophils into entheses and joints. Furthermore, IL-23 also influences structural changes in the joints of patients with psoriatic arthritis by enhancing osteoclast mediated bone resorption leading to bone erosion, as well as by modulating bone-forming osteoblasts resulting in bony spur formation and ankylosis. In summary, IL-23 represents a highly specialized inflammatory mediator, which is involved in the communication of inflammation across organs. IL-23 is positioned at the initiation point of a pro-inflammatory cytokine cascade that precipitates the development of psoriatic arthritis.
Efficacy of subcutaneous tocilizumab in a patient with severe gout refractory to anakinra
Enrique Calvo-Aranda, Fernando Manuel Sanchez-Aranda
doi : 10.1093/rheumatology/keab383
Rheumatology, Volume 60, Issue 11, November 2021, Pages e375–e377
Diffuse oesophageal involvement in anti-NXP2 myositis and response to combined immunosuppressive therapy
Antonis Fanouriakis, Argyro Lazarini, Ioannis Sofianos, Constantinos Papadopoulos, Eleni Bagiazidou, Alexia Balanika, Antonia Elezoglou
doi : 10.1093/rheumatology/keab422
Rheumatology, Volume 60, Issue 11, November 2021, Pages e378–e380
Extensive soft tissue xanthomatosis masquerading as tophaceous gout in a normolipidemic man
Michael Putman, Nathan Kong, Jon Lomasney, Neil J Stone, John Varga
doi : 10.1093/rheumatology/keab473
Rheumatology, Volume 60, Issue 11, November 2021, Pages e381–e383
Deep tissue Koebner phenomenon in osseous sarcoidosis
Diarmuid O’Brien, Tahir Aziz, David Kane, Ronan H Mullan
doi : 10.1093/rheumatology/keab420
Rheumatology, Volume 60, Issue 11, November 2021, Pages e384–e386
Calcinosis in refractory dermatomyositis improves with tofacitinib monotherapy: a case series
Matthew Shneyderman, Shivani Ahlawat, Lisa Christopher-Stine, Julie J Paik
doi : 10.1093/rheumatology/keab421
Rheumatology, Volume 60, Issue 11, November 2021, Pages e387–e388
Efficacy of baricitinib for refractory large-vessel vasculitis
Alexis Régent, Benjamin Terrier, Paul Legendre, Myriam Wartski, Pascal Cohen, Luc Mouthon, Claire Le Jeunne
doi : 10.1093/rheumatology/keab541
Rheumatology, Volume 60, Issue 11, November 2021, Pages e389–e391
Multisystem inflammatory syndrome in an adult with involvement of the skin, lymph nodes, muscle, heart, liver and kidneys
Christopher W Kinter, Grace E Saxon, Madiha Ahmad, Hebist Berhane, Lauren Gensler, Arezou Khosroshahi
doi : 10.1093/rheumatology/keab426
Rheumatology, Volume 60, Issue 11, November 2021, Pages e392–e394
A rare manifestation of sensory neuropathy in primary Sjögren syndrome
Mónica Guijarro-Del Amo, Juan Carlos Piñeiro-Fernández
doi : 10.1093/rheumatology/keab434
Rheumatology, Volume 60, Issue 11, November 2021, Pages e395–e396
A pitfall in diagnosing psoriatic arthritis resolved by ultrasound: acrodermatitis continua suppurativa of Hallopeau
Svenja Müller, Dagmar Wilsmann-Theis, Pantelis Karakostas, Sietske Poortinga, Galina Balakirski, Valentin Sebastian Schäfer
doi : 10.1093/rheumatology/keab490
Rheumatology, Volume 60, Issue 11, November 2021, Pages e397–e399
Successful treatment of penile Mondor’s disease with infliximab in a patient with Behçet’s disease
Deniz Aral Özbek, Emre Bilgin, Mehmet Ruhi Onur, Ömer Karada?, Sedat Kiraz
doi : 10.1093/rheumatology/keab393
Rheumatology, Volume 60, Issue 11, November 2021, Pages e400–e401
VEXAS syndrome in a woman
Thomas Barba, Yvan Jamilloux, Cécile-Audrey Durel, Estelle Bourbon, Fanélie Mestrallet, Pierre Sujobert, Arnaud Hot
doi : 10.1093/rheumatology/keab392
Rheumatology, Volume 60, Issue 11, November 2021, Pages e402–e403
UNC13D mutation in a patient with juvenile polymyositis with recurrent macrophage activation syndrome
Xi Yang, Han Yao, Qian Zhao, Qin Zhao, Xin Yan, Zhiyong Zhang, Peiyan Kong, Xi Zhang, Hirokazu Kanegane, Xiaodong Zhao, Xuemei Tang
doi : 10.1093/rheumatology/keab391
Rheumatology, Volume 60, Issue 11, November 2021, Pages e404–e406
Comment on: ANCA in systemic sclerosis, when vasculitis overlaps with vasculopathy: a devastating combination of pathologies
Mohammed Osman, Desiree Redmond, Jan Willem Cohen Tervaert
doi : 10.1093/rheumatology/keab525
Rheumatology, Volume 60, Issue 11, November 2021, Pages e407–e409
Comment on: Prevalence and real-world management of vedolizumab-associated enthesitis in successfully treated IBD patients
Hanene Lassoued Ferjani, Dorra Ben Nessib, Kaouther Maatallah, Wafa Hamdi
doi : 10.1093/rheumatology/keab333
Rheumatology, Volume 60, Issue 11, November 2021, Pages e410–e411
Comment on: Persistence of circulating T-follicular helper cells after rituximab is associated with relapse of IgG4-related disease
Mitsuhiro Akiyama, Yuko Kaneko
doi : 10.1093/rheumatology/keab687
Rheumatology, Volume 60, Issue 11, November 2021, Pages e412–e413
Comment on: Association of serum levels of inflammatory markers and adipokines with joint symptoms and structures in participants with knee osteoarthritis
Tyler Barker
doi : 10.1093/rheumatology/keab656
Rheumatology, Volume 60, Issue 11, November 2021, Pages e414–e415
Comment on: Association of serum levels of inflammatory markers and adipokines with joint symptoms and structures in participants with knee osteoarthritis: reply
Jimin Zhu, Guangfeng Ruan, Changhai Ding
doi : 10.1093/rheumatology/keab657
Rheumatology, Volume 60, Issue 11, November 2021, Pages e416–e417
Cardiovascular risk and mortality in rheumatoid arthritis compared with diabetes mellitus and the general population
Weijie Wang, Chih-Jung Yeh, James Cheng-Chung Wei
doi : 10.1093/rheumatology/keab650
Rheumatology, Volume 60, Issue 11, November 2021, Page e418
Comment on: Cardiovascular risk and mortality in rheumatoid arthritis compared with diabetes mellitus and the general population: reply
Brian Bridal Løgstrup, Torkell Ellingsen, Alma B Pedersen, Bianca Darvalics, Kevin K W Olesen, Hans Erik Bøtker, Michael Maeng
doi : 10.1093/rheumatology/keab652
Rheumatology, Volume 60, Issue 11, November 2021, Pages e419–e420
Comment on: Epidemiology of biopsy-confirmed giant cell arteritis in southern Sweden—an update on incidence and first prevalence estimate
Victor Yang, Christopher McMaster, Claire E Owen, Jessica L Leung, Lionel Schachna, Russell R C Buchanan, David F L Liew
doi : 10.1093/rheumatology/keab558
Rheumatology, Volume 60, Issue 11, November 2021, Pages e421–e422
Comment on: Epidemiology of biopsy-confirmed giant cell arteritis in southern Sweden—an update on incidence and first prevalence estimate: reply
Pavlos Stamatis, Aleksandra Turkiewicz, Martin Englund, Carl Turesson, Aladdin J Mohammad
doi : 10.1093/rheumatology/keab559
Rheumatology, Volume 60, Issue 11, November 2021, Pages e423–e424
Comment on: Hematological malignancies in giant cell arteritis: a French population-based study
Eric Liozon, Simon Parreau, Guillaume Gondran, Holy Bezanahary, Marie-Pierre Gourin
doi : 10.1093/rheumatology/keab439
Rheumatology, Volume 60, Issue 11, November 2021, Pages e425–e426
